Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Lymphocyte Growth Factor [EPC]
Canakinumab is a human monoclonal antibody that acts as an interleukin-1 beta (IL-1β) inhibitor, primarily used to treat rare autoinflammatory diseases and systemic juvenile idiopathic arthritis.
Name
Canakinumab
Raw Name
CANAKINUMAB
Category
Lymphocyte Growth Factor [EPC]
Drug Count
6
Variant Count
6
Last Verified
February 17, 2026
RxCUI
1864324, 1864326
UNII
M89N0Q7EQR, S7V92P67HO, WQZ3G9PF0H, 37CQ2C7X93, VB06AV5US8, 4QQN74LH4O, JL5DK93RCL, W2469WNO6U, W6J1279A6K, 70FD1KFU70, 2P3VWU3H10, KK0Z92II8M, ML4QRZ1HCL, O80TY208ZW, T7S323PKJS, 7M867G6T1U, YF70189L0N, 8R564U2E1P, 2S713A4VP3, 6EC706HI7F, 269XH13919, 308LM01C72, 2510RH3I89, 751635Z921, 0MVO31Q3QS, 92QVL9080Y, 21K6M2I7AG, 6WS4C399GB, 2A88ZO081O, VP2CN2G7Y8, 7B69B0BD62, MA9CQJ3F7F, FGL3685T2X, 608DGJ6815, I76KB35JEV, 333DO1RDJY, 1NM3M2487K, 050QZ2EDK7, JWF5YAW3QW
About Canakinumab
Canakinumab is a human monoclonal antibody that acts as an interleukin-1 beta (IL-1β) inhibitor, primarily used to treat rare autoinflammatory diseases and systemic juvenile idiopathic arthritis.
Detailed information about Canakinumab
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Canakinumab.
Originally approved by the U.S. Food and Drug Administration (FDA) in 2009 under the brand name Ilaris, canakinumab represented a significant breakthrough in the management of Cryopyrin-Associated Periodic Syndromes (CAPS). Over the subsequent decade, its clinical utility has expanded significantly through rigorous clinical trials, leading to approvals for Systemic Juvenile Idiopathic Arthritis (sJIA), Adult-Onset Still’s Disease (AOSD), and several other periodic fever syndromes. Unlike broad immunosuppressants, canakinumab targets a very specific pathway in the innate immune system, which allows for targeted therapy with a distinct safety profile compared to traditional corticosteroids or non-specific biologics.
At the molecular level, canakinumab functions by recognizing and binding to the human IL-1β protein with high specificity. Interleukin-1 beta is a key mediator of the body's inflammatory response; in healthy individuals, it helps coordinate the immune system's reaction to injury or infection. However, in patients with certain genetic mutations or autoinflammatory diseases, IL-1β is produced in excess, leading to chronic fever, joint pain, skin rashes, and potentially life-threatening organ damage (such as amyloidosis).
When canakinumab binds to IL-1β, it prevents the cytokine from interacting with the IL-1 receptors located on the surface of various cells. This blockade effectively 'turns off' the downstream signaling cascade that would otherwise lead to the production of other inflammatory markers like C-reactive protein (CRP) and Serum Amyloid A (SAA). Because canakinumab does not bind to interleukin-1 alpha (IL-1α) or the interleukin-1 receptor antagonist (IL-1Ra), it maintains some aspects of the body's natural immune defense while specifically suppressing the pathological overproduction of IL-1β.
Understanding the pharmacokinetics of canakinumab is essential for optimizing its long-term administration, as it features a notably long duration of action.
Canakinumab is FDA-approved for a variety of conditions characterized by IL-1β mediated inflammation:
Canakinumab is exclusively available as an injection for subcutaneous use. It is typically supplied in two formats:
> Important: Only your healthcare provider can determine if Canakinumab is right for your specific condition. The diagnosis of autoinflammatory syndromes requires specialized genetic testing and clinical evaluation by a rheumatologist or immunologist.
The dosage of canakinumab is highly individualized based on the specific condition being treated and the patient's body weight.
Canakinumab is approved for pediatric use in several indications, with dosing primarily based on weight.
No formal studies have been conducted in patients with renal impairment. However, because monoclonal antibodies are not cleared by the kidneys, dose adjustments are generally not required for patients with mild to moderate kidney disease. Severe renal impairment should be monitored closely.
Canakinumab has not been specifically studied in patients with hepatic (liver) impairment. Since the drug is not metabolized by liver enzymes, significant changes in pharmacokinetics are not expected, but clinical monitoring for overall safety is advised.
Clinical trials did not include sufficient numbers of patients aged 65 and over to determine if they respond differently than younger patients. Dosing should be approached cautiously, starting at the lower end of the range, reflecting the greater frequency of decreased organ function and concomitant diseases.
Canakinumab must be administered by a healthcare professional or under their close supervision.
If a dose of canakinumab is missed, it should be administered as soon as possible. The next dose should then be scheduled according to the prescribed interval (e.g., 4 or 8 weeks later) from the date of the last injection. Do not 'double up' on doses to catch up.
There is limited experience with canakinumab overdose. In clinical trials, doses up to 10 mg/kg have been administered without evidence of acute toxicity. In the event of an overdose, the patient should be monitored for any signs or symptoms of adverse reactions, and appropriate symptomatic treatment should be provided immediately.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or frequency without medical guidance, as this can lead to a return of inflammatory symptoms or increased risk of infection.
Because canakinumab modulates the immune system, the most common side effects are often related to the respiratory system and general well-being. According to clinical trial data (FDA, 2024), these include:
> Warning: Stop taking Canakinumab and call your doctor immediately if you experience any of these serious symptoms.
Long-term use of canakinumab requires ongoing vigilance. Prolonged suppression of IL-1β may lead to a sustained, albeit slight, increase in the risk of upper respiratory infections. Additionally, some patients may develop 'anti-drug antibodies' over several years. While these antibodies are rarely neutralizing (meaning they usually don't stop the drug from working), they can occasionally lead to a decrease in the drug's efficacy over time.
No FDA black box warnings for Canakinumab. Unlike some other biologics (such as TNF-blockers), canakinumab does not currently carry a boxed warning for malignancy or specific fungal infections, though the general risk of serious infection remains a primary clinical concern.
Report any unusual symptoms, especially those suggesting a new infection, to your healthcare provider immediately. Regular blood tests are necessary to ensure your white blood cell counts remain within a safe range.
Canakinumab is a potent immunomodulator. Before starting treatment, patients must be screened for active or latent infections. Because IL-1β is a critical component of the body's early warning system for infection, canakinumab can mask the typical signs of illness, such as a high fever. This means an infection could become serious before a patient realizes they are sick.
No FDA black box warnings for Canakinumab. However, the FDA-approved labeling emphasizes the risk of serious infections and the necessity of monitoring.
To ensure safety while on canakinumab, the following lab tests are typically required:
Canakinumab is not known to have a significant effect on the ability to drive or operate machinery. However, if a patient experiences dizziness or vertigo as a side effect, they should avoid these activities until the symptoms resolve.
There are no known direct contraindications between canakinumab and alcohol. However, since both can affect liver health in some contexts, moderation is advised. Discuss your alcohol consumption with your doctor.
Canakinumab does not typically cause a 'withdrawal syndrome.' However, stopping the medication will lead to a return of the underlying inflammatory symptoms, often within weeks to months, as the drug clears the system. Patients should never stop treatment without a tapering plan or alternative therapy discussed with their rheumatologist.
> Important: Discuss all your medical conditions, including any history of recurrent infections or exposure to tuberculosis, with your healthcare provider before starting Canakinumab.
There are no documented interactions between canakinumab and specific foods, including grapefruit or dairy. Because it is administered subcutaneously, the absorption process bypasses the digestive system's primary metabolic hurdles.
Canakinumab will significantly lower laboratory markers of inflammation, such as C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR). While this is the intended effect, it means these tests can no longer be used as reliable indicators of a new, unrelated infection. A patient might have a serious infection but still show a 'normal' CRP level because of the drug.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter cold medicines and vitamins.
There are specific scenarios where canakinumab must NEVER be used due to the risk of catastrophic health outcomes:
These conditions require a careful risk-benefit analysis by a medical specialist:
There is no known cross-sensitivity between canakinumab and other IL-1 blockers like anakinra or rilonacept, as they have different molecular structures. However, patients who have had a reaction to other fully human monoclonal antibodies should be monitored closely during their first injection.
> Important: Your healthcare provider will evaluate your complete medical history, including any history of fungal infections or residence in areas where certain diseases like histoplasmosis are common, before prescribing Canakinumab.
Canakinumab is classified as a drug where human data is limited. Animal studies using marmosets did not reveal evidence of harm to the fetus or increased malformations at doses significantly higher than the human dose. However, monoclonal antibodies (IgG) are known to cross the placental barrier, especially during the second and third trimesters.
It is not known whether canakinumab is excreted in human milk. However, because maternal IgG is known to be present in breast milk, it is likely that canakinumab is also present in small amounts.
Canakinumab is well-established for use in children for specific indications:
Patients over 65 years of age should be monitored closely. While no specific age-related differences in effectiveness have been identified, the elderly are naturally at a higher risk for infections and often have reduced renal or cardiac reserve. Polypharmacy (taking multiple medications) in the elderly also increases the risk of drug-drug interactions involving CYP450 substrates.
Renal impairment is not expected to influence the clearance of canakinumab, as monoclonal antibodies are too large to be filtered by the glomeruli of the kidney. No dose adjustment is recommended for patients with mild-to-moderate renal insufficiency. Data for patients on dialysis is currently unavailable.
No formal studies have been conducted in patients with hepatic impairment. However, since the liver is not the primary site of clearance for canakinumab, significant changes in drug levels are unlikely. Clinical judgment and monitoring for general toxicity are recommended.
> Important: Special populations require individualized medical assessment. Always inform your doctor if you are planning to become pregnant or are currently nursing.
Canakinumab is a recombinant, human anti-human-interleukin-1 beta (IL-1β) monoclonal antibody of the IgG1/kappa isotype. It works by binding with high affinity and specificity to human IL-1β. By doing so, it neutralizes the activity of IL-1β by blocking its interaction with the IL-1 receptors. This prevents the activation of the signaling pathways that lead to the expression of inflammatory mediators. Importantly, canakinumab does not bind to IL-1α or the IL-1 receptor antagonist (IL-1Ra), which allows for a more targeted anti-inflammatory effect compared to broader inhibitors.
The pharmacodynamic effect of canakinumab is characterized by a rapid and sustained decrease in inflammatory markers. In patients with CAPS, a single dose of 150 mg leads to a significant reduction in C-reactive protein (CRP) and Serum Amyloid A (SAA) within 24 to 48 hours. These markers often remain within the normal range for up to 8 weeks, correlating with the clinical resolution of symptoms like fever and joint pain.
| Parameter | Value |
|---|---|
| Bioavailability | ~66% (Subcutaneous) |
| Protein Binding | N/A (Monoclonal antibody) |
| Half-life | ~26 days |
| Tmax | ~7 days |
| Metabolism | Proteolysis (Non-CYP) |
| Excretion | Cellular catabolism |
Canakinumab is classified as an Interleukin-1 (IL-1) blocker. It is part of the broader category of biological DMARDs (Disease-Modifying Antirheumatic Drugs). It is distinct from other IL-1 blockers like Anakinra (a recombinant IL-1 receptor antagonist) and Rilonacept (a dimeric fusion protein) due to its longer half-life and its specific targeting of the IL-1β ligand itself.
Medications containing this ingredient
Common questions about Canakinumab
Canakinumab, sold under the brand name Ilaris, is primarily used to treat a group of rare autoinflammatory diseases known as periodic fever syndromes. These include Cryopyrin-Associated Periodic Syndromes (CAPS), Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), and Familial Mediterranean Fever (FMF). It is also FDA-approved for treating Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-Onset Still’s Disease (AOSD). Additionally, it is used for patients with frequent gout flares who cannot take other standard medications. The drug works by blocking a specific protein in the body that causes excessive inflammation.
The most common side effects reported in clinical trials include symptoms of the upper respiratory tract, such as a sore throat, runny nose, and nasal congestion (nasopharyngitis). Many patients also experience diarrhea, headaches, and mild dizziness. Because the drug affects the immune system, minor infections like the flu or cold are more frequent. Some patients may also notice redness or itching at the site where the injection was given. While these are usually mild, it is important to report any persistent symptoms to your healthcare provider.
There is currently no evidence of a direct chemical interaction between alcohol and canakinumab. However, alcohol can sometimes worsen the symptoms of certain conditions canakinumab treats, such as gout or systemic inflammation. Furthermore, both alcohol and chronic inflammatory conditions can put stress on the liver. It is generally recommended to consume alcohol only in moderation while on this therapy. You should discuss your lifestyle habits with your doctor to ensure alcohol consumption is safe for your specific health profile.
The safety of canakinumab during pregnancy has not been fully established through large-scale human clinical trials. Animal studies have not shown direct harm to the fetus, but it is known that monoclonal antibodies can cross the placenta, especially in the later stages of pregnancy. This could potentially affect the immune system of the newborn baby. Doctors typically only prescribe canakinumab to pregnant women if the benefits of controlling a severe inflammatory disease outweigh the potential risks to the fetus. If you are pregnant or planning to become pregnant, a detailed discussion with a specialist is necessary.
For many patients, the effects of canakinumab are noticed quite rapidly. In conditions like CAPS or gouty arthritis, symptoms such as fever and joint pain may begin to improve within 24 to 48 hours after the first injection. Laboratory markers of inflammation, such as C-reactive protein (CRP), typically show a significant decrease within the first week. However, the full therapeutic effect for chronic conditions like sJIA might take a few weeks to become fully apparent. Your doctor will monitor your response through both clinical symptoms and blood tests.
You should not stop taking canakinumab without first consulting your healthcare provider. While the drug does not cause physical withdrawal symptoms, stopping it will likely result in a return of the original inflammatory symptoms. Because canakinumab has a very long half-life, it stays in your system for several weeks, so symptoms may not return immediately but could flare up significantly once the drug levels drop. If you need to discontinue the medication due to side effects or other reasons, your doctor will provide a plan to manage your condition.
If you miss an appointment for your canakinumab injection, you should contact your healthcare provider as soon as you remember to reschedule. The dose should be administered as soon as possible, and then your next dose should be scheduled based on the original interval (usually every 4 or 8 weeks) from that new date. Do not attempt to administer two doses at once to make up for a missed one. Keeping a consistent schedule is important for maintaining the anti-inflammatory effects and preventing flares of your condition.
Weight gain is not a commonly reported side effect of canakinumab in clinical trials. Unlike corticosteroids (such as prednisone), which are often used for the same inflammatory conditions and are well-known for causing weight gain and fluid retention, canakinumab targets a specific cytokine and does not typically affect metabolism in that way. If you notice significant or rapid weight gain while on this medication, it may be due to other factors or a change in your underlying health status. You should discuss any significant weight changes with your doctor.
Canakinumab can interact with other medications, particularly those that also affect the immune system. Taking it alongside other biologics, such as TNF inhibitors (like Humira or Enbrel), is generally avoided because it significantly increases the risk of serious infections. It can also affect how your liver processes other drugs like warfarin or certain seizure medications by changing the activity of liver enzymes. Always provide your doctor with a complete list of all prescription drugs, over-the-counter medicines, and herbal supplements you are currently taking to avoid dangerous interactions.
As of 2026, canakinumab is not available as a generic medication. It is a complex biologic drug protected by patents and exclusivity agreements held by the original manufacturer, Novartis. Biologic drugs are much more difficult to replicate than standard chemical pills, and 'generic' versions are referred to as biosimilars. While biosimilars for other monoclonal antibodies exist, there is currently no FDA-approved biosimilar for canakinumab. This means the medication remains expensive and is typically covered under specialty pharmacy benefits of insurance plans.